Year: 2025

TORONTO, Oct. 24, 2025 (GLOBE NEWSWIRE) — Allied Gold Corporation (TSX: AAUC, NYSE: AAUC) (“Allied” or the “Company”) is pleased to announce that it has closed its previously announced overnight marketed public offering of common shares (the “Offering”). Pursuant to the Offering, the Company issued 6,400,000 common shares in the capital of the Company (the “Shares”) at a price of C$27.35 per Share for aggregate gross proceeds of C$175,040,000. The Offering was completed through Stifel Nicolaus Canada Inc., Canaccord Genuity Corp. and National Bank Financial Inc., as joint bookrunners, together with a syndicate of underwriters made up of CIBC World Markets Inc. and Cormark Securities Inc. (together with the joint bookrunners, the “Underwriters”). The Company intends to use the net proceeds of the Offering to i) fund its optimization...

BOWLING GREEN, Ky., Oct. 24, 2025 (GLOBE NEWSWIRE) — Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, today announced the date for the release of its third quarter 2025 financial results. Third Quarter 2025 Results        Holley will host a conference call and live webcast on Friday, November 7, 2025, at 8:30 am (Eastern Time) to discuss the Company’s third quarter 2025 financial results. The Company’s earnings release and presentation for the third quarter 2025 will be issued before the market opens on Friday, November 7, 2025, and will be available on the Investor Relations page of the Company’s website at investor.holley.com. Hosting the call will be Holley Inc. President and Chief Executive Officer, Matthew Stevenson, and Chief Financial Officer, Jesse Weaver.Date: Friday,...

Lawson Drilling Set to Begin in Early November as MAX Power Advances Canada’s First Natural Hydrogen Well MAX Power Saskatchewan Natural Hydrogen Documentary Videohttps://www.maxpowermining.com/NaturalHydrogen-NewEra/ SASKATOON, Saskatchewan, Oct. 24, 2025 (GLOBE NEWSWIRE) —  MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) (“MAX Power” or the “Company”) is pleased to announce that it has received the drilling license for the first well of its planned multi-well Natural Hydrogen drill program in southern Saskatchewan. Procurement of services and suppliers, including the drilling contractor, is complete, and the Lawson target well in the heart of the 200-km-long Genesis Trend will be spud on or about November 7, 2025. Mr. Mansoor Jan, President and CEO of MAX Power, commented: “Receiving the well license marks a major...

TEL AVIV, Israel, Oct. 24, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the closing of the transactions under the asset and share purchase agreement by and among the Company, Miza III Ventures Inc. and SciSparc Nutraceuticals Inc. (the “Agreement”). Pursuant to the Agreement, SciSparc received a controlling interest in Neurothera Labs Inc. (formerly known as Miza III Ventures Inc.) (TSXV:NTLX) (“Neurothera”), a publicly traded company on the TSX Venture Exchange (the “TSXV”) in Canada, and the Company transferred to Neurothera its advanced clinical stage pharmaceutical portfolio and its equity stake of approximately 51% in...

The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseasesCAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) —  Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by advancing a proven immune mechanism with the potential to address a broad range of inflammatory disorders with high unmet need. “This agreement reflects our strong commitment to building a comprehensive immunology pipeline with a strategic focus on both innate and adaptive immune pathways,” said Jane Grogan, Ph.D., Executive Vice President and Head of Research at Biogen. “C5aR1 is a well-validated target...